Donation of Imusil
Dr Marvin S Antelman, the inventor of a treatment for HIV/AIDS, has generously donated six single injections of Imusil for Compassion Response Network AIDS trials. Three of these injections have been sent to the Harare project and await funding for treatment of three HIV/AIDS patients, and three injections have been sent to Kinshasa where three HIV/AIDS patients have been treated in an Imusil trial conducted during the year 2004. One injection is all that is needed.
Imusil is a product of Marantech Holdings LLC, Providence, Rhode Island, USA. For information, contact them at firstname.lastname@example.org. You are also invited to look up the Marantech website at http://www.Marantech.com
What is Imusil?
Marantech has identified and patented use of a number of Electron Jumping Compounds (EJCs) that have been found in independent laboratory testing to exhibit powerful antimicrobial activity. However, to date the bulk of Marantech’s testing of EJCs for pharmacological safety and efficacy has centered on tetrasilver tetroxide (abbreviated TST, a multivalent metallic oxide uniquely structured as a semi-conducting molecular crystal device. Independent laboratory and clinical testing indicates that TST molecules selectively target and kill rapidly proliferating organisms (e.g., viruses, bacteria, fungi and protozoa) through a multitude of nano-level electrical discharges followed by physical combination (chelation) and release of singlet oxygen at the pathogenic site. Normal tissues are generally unaffected. The unusual suspected kill method may thwart the development of pathogens resistant to Tetrasil therapy.
Antimicrobial Activity: It has been known for several years that TST is a potent antimicrobial agent that kills a broad spectrum of viruses, fungi, algae and bacteria (including drug resistant strains) in-vitro at concentrations that have been certified safe by the EPA for usage in swimming pools ("EPA Levels"). Clinical studies commissioned by Marantech and conducted by Exetec Labs in Honduras, indicate that topically applied TST can lead to dramatic and rapid improvements in such infection-caused skin conditions as cold sores, herpes lesions, shingles, follicultis, diabetic ulcers, bedsores, tinea versicolor, and ringworm. In topical form, TST is formulated as Tetrasil and is available through their website, www.tetrasil.com. Moreover, building on earlier informal testing against systemic infections (including Candida albicans, dysentery and AIDS), Exetec was commissioned to conduct clinical studies of TST as an intravenous treatment for AIDS (Imusil).
Oncological Activity: Independent in-vitro lab testing also found that TST is lethal to a dozen common forms of human cancer cells. Marantech therefore expanded the Exetec clinical studies to include topical treatment of skin tumors. Reported results include healing of skin lesions and apparent elimination of atypical cells in many patients with neurofibromatosis and early-stage malignant melanomas, basal cell and squamous cell carcinomas.
Other Dermatological Activity: Exetec also reported that topically applied TST (formulated as Tetrasil) appears to promote healing of skin conditions that are neither cancerous nor infected, including atopic dermatitis (eczema) , psoriasis, and third-degree burns, apparently by triggering an increase in the production of new, healthy tissue.
Dr Antelman's Theory on AIDS
"Our approach to AIDS is non-conventional. There is HIV without AIDS and AIDS without HIV. Nobel Prize winner Kary Mullis has pointed this out as well as his position that AZT is a failure. Accordingly we have patients who display viral load reduction and those that do not who are nevertheless cured of AIDS because in certain cases HIV will be neutralised and remain in the body with no visible change as far as the present "viral load" test technology allows for."
Dr Antelman indicated that there exist 5 standard etiologies (reasons of causation) for AIDS:
"My own recent observations are that irrespective of the etiology, certain AIDS patients have EBV causing them to have chronic fatigue syndrome. When they are cured they will not show viral load differences because EBV is latent or active."
"Those patients that display the same viral load show differences in their white blood cell count and if not in weight gain when they have wasting syndrome. Apparently, the current diagnostic methods science relies on are not adequate to show a marker for certain AIDS patients who have recovered leading normal lives. "
Treatment of AIDS
From an article, Antiviral Tetrasilver Tetroxide Therapy, by Dr Marvin S Antelman. The full 5-page article is available through Dr Antelman or Compassion Response Network.
AIDS-Non Terminal Patients: "Clinical testing was performed at Exetec Lab, SA in Honduras under the supervision of Dr. L Roland Valenzuela. Thirty patients were selected from three etiological AIDS groups, 10 for each group namely, Candidiasis, Wasting Syndrome and p. carinii pneumonia. Each patient was given an intravenous infusion of Imusil administered over a three hour period. All patients experienced temperature elevation within 48 hours of administering the Imusil, which was indicative that the immune system was now functioning along with the fact that all patients also started to have dramatic increases in their white blood cell counts. At the end of 30 days of observation, all patients were cured of AIDS. All patients presenting Wasting Syndrome were completely cured of the Syndrome; the average patient gaining approximately one half pound per day. Three patients were completely cured of their pneumonia. Because the protocol was changed from direct injection to slow i.v. infusion of the Imusil, there were no side effects of hepatomegaly."
Imusil®, Tetrasil® and Electron-Jumping Compounds® are registered trademarks of Marantech Holding LLC. Protected by several US and international patents, and additional patents pending.